"10.1371_journal.pone.0021203","plos one","2011-06-24T00:00:00Z","Kalpana Gupta; Amitabha Chakrabarti; Sonia Rana; Ritu Ramdeo; Bryan L Roth; Munna L Agarwal; William Tse; Mukesh K Agarwal; David N Wald","Department of Pathology, Case Western Reserve School of Medicine, Cleveland, Ohio, United States of America; Invenio Therapeutics, Cleveland, Ohio, United States of America; Departments of Pharmacology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina, United States of America; Department of Genetics, Case Western Reserve School of Medicine, Cleveland, Ohio, United States of America; Department of Medicine, West Virginia University, Morgantown, West Virginia, United States of America; University Hospitals Case Medical Center, Cleveland, Ohio, United States of America","Conceived and designed the experiments: DNW MLA MKA WT BLR KG. Performed the experiments: SR AC KG DNW RR. Analyzed the data: DNW KG. Wrote the paper: KG DNW.","The author has read the journal's policy and has the following conflicts: David Wald, a former employee, and Mukesh Agarwal, a current employee of Invenio Therapeutics, both have an equity interest in Invenio Therapeutics, which previously had an option to license agreement for intellectual property that included securinine. This agreement is now expired. David Wald is listed as an inventor on a patent application submitted by Case Western Reserve University related to securinine, the details of which are: Patent Application No. 60/943,415 entitled, “Myeloid Differentiation Inducing Agents.” Case Western Reserve University has 100% ownership of this intellectual property as the discovery was made at their institution. There are no products in development or marketed products to declare. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. The authors do not currently have any other declarations.","2011","06","Kalpana Gupta","KG",9,TRUE,6,5,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
